SGLT2抑制剂与DPP4抑制剂在2型糖尿病患者中的肾脏结局关联比较
基于香港全境电子病历的回顾性队列研究,采用倾向性评分匹配比较6333例SGLT2i使用者与25332例DPP4i使用者的肾脏结局,中位随访3.8年。SGLT2i与较低的终末期肾病和急性肾衰竭风险及较慢的eGFR下降相关,白蛋白尿关联在各分析中不一致。
要点
- SGLT2i组终末期肾病风险低于DPP4i组(HR 0.51)。
- SGLT2i组急性肾衰竭风险低于DPP4i组(HR 0.59)。
- SGLT2i与较慢的eGFR下降相关,白蛋白尿关联不一致。
核心结论
- 在真实世界环境中,与DPP4i相比,SGLT2i使用与终末期肾病和急性肾衰竭风险降低及eGFR下降较慢相关。
- 在有或无指数日期前快速eGFR下降的患者中,上述关联仍具有统计学显著性。
研究设计与样本
- 采用回顾性队列研究设计,使用「流行新使用者」设计以考虑既往研究药物暴露。
- 使用倾向性评分匹配平衡基线特征,收集2015年至2018年间使用SGLT2i和DPP4i的2型糖尿病患者的电子健康数据。
- 匹配队列包括6333例SGLT2i使用者和25332例DPP4i使用者,中位随访3.8年。
主要发现
- 与DPP4i相比,SGLT2i使用与较低的终末期肾病风险相关(HR 0.51;95% CI 0.42-0.62;P < .001)。
- 与DPP4i相比,SGLT2i使用与较低的急性肾衰竭风险相关(HR 0.59;95% CI 0.48-0.73;P < .001)。
- SGLT2i使用与较慢的eGFR下降相关。
- 在有或无指数日期前快速eGFR下降的患者中以及在从DPP4i添加或转换为SGLT2i的患者中,上述关联仍具有统计学显著性。
- 白蛋白尿的关联在各分析中不一致。
局限性
- 原文指出与单个降糖药物类别的头对头比较需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diabetic kidney disease is a major burden among diabetic patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were shown to reduce renal outcomes in clinical trials and real-world studies. However, head-to-head comparisons with individual classes of glucose-lowering agents warranted further investigation. OBJECTIVE: This work aimed to investigate the associations between SGLT2is use vs dipeptidyl peptidase-4 inhibitors (DPP4is) use and 4 renal outcomes: end-stage renal disease (ESRD), albuminuria, acute renal failure (ARF), and the rate of estimated glomerular filtration rate (eGFR) change using a territory-wide electronic medical database in Hong Kong. METHODS: For this retrospective cohort study, the "prevalent new-user" design was adopted to account for previous exposure to study drugs. Propensity score matching was used to balance baseline characteristics. Electronic health data of type 2 diabetes patients using SGLT2is and DPP4is between 2015 and 2018 were collected. RESULTS: The matched cohort consisted of 6333 SGLT2is users and 25 332 DPP4is users, with a median follow-up of 3.8 years. Compared to DPP4is, SGLT2is use was associated with lower risks of ESRD (hazard ratio [HR]: 0.51; 95% CI, 0.42-0.62; P < .001) and ARF (HR: 0.59; 95% CI, 0.48-0.73; P < .001), and a slower decline in eGFR. The associations remained statistically significant among patients with or without rapid eGFR decline and patients who added or switched to SGLT2is from DPP4is. The association with albuminuria was inconsistent across analyses. CONCLUSION: Compared to DPP4is, SGLT2is use was associated with reduced risks of ESRD and ARF, and a slower eGFR decline in a real-world setting. The associations remained statistically significant in patients with or without preindex rapid eGFR decline.
引用
- Au PCM, Tan KCB, Cheung BMY, et al. Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2022. PMID: 35303075. doi:10.1210/clinem/dgac164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。